Claims
- 1. A compound having the formula I: ##STR22## wherein X is
- (1) a bond;
- m is
- 0 to 5;
- A is
- (1) phenyl, or
- (2) a benzene ring fused to a C.sub.5 -C.sub.10 carbocyclic ring;
- R.sup.1 is
- (1) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 groups selected from
- (a) hydroxy,
- (b) halogen,
- (c) cyano,
- (d) QR.sup.2,
- (e) C.sub.3 -C.sub.8 cycloalkyl,
- (f) A optionally substituted with up to 5 groups selected from halogen, C.sub.1 -C.sub.10 alkyl and C.sub.1 -C.sub.10 alkoxy,
- (g) Q'COR.sup.3,
- (h) S(O).sub.n R.sup.3, where n is 0 to 2,
- (i) NR.sup.2 SO.sub.2 R.sup.3,
- (j) NR.sup.2 CO.sub.2 R.sup.2, and
- (k) CO.sub.2 R.sup.2,
- (2) C.sub.3 -C.sub.8 cycloalkyl,
- (3) halogen,
- (4) cyano,
- (5) QR.sup.2,
- (6) S(O).sub.n R.sup.3, where n is 0 to 2,
- (7) Q'COR.sup.3,
- (8) NR.sup.2 SO.sub.2 R.sup.3,
- (9) NR.sup.2 CO.sub.2 R.sup.2,
- (10) A optionally substituted with up to 5 groups independently selected from
- (a) R.sup.2,
- (b) QR.sup.2, and
- (c) halogen; or
- (11) CO.sub.2 R.sup.2 ;
- R.sup.2 is
- (1) hydrogen,
- (2) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 groups selected from
- (a) hydroxy,
- (b) halogen,
- (c) CO.sub.2 R.sup.4,
- (d) S(O).sub.n -C.sub.1 -C.sub.10 alkyl, where n is 0 to 2,
- (e) C.sub.3 -C.sub.8 cycloalkyl,
- (f) C.sub.1 -C.sub.10 alkoxy, and
- (g) A optionally substituted with up to 5 groups selected from halogen, C.sub.1 -C.sub.10 alkyl and C.sub.1 -C.sub.10 alkoxy,
- (3) C.sub.3 -C.sub.8 cycloalkyl, or
- (4) A optionally substituted with up to 5 groups selected from
- (a) halogen,
- (b) nitro,
- (c) NR.sup.4 R.sup.4,
- (d) C.sub.1 -C.sub.10 alkoxy,
- (e) S(O).sub.n -C.sub.1 -C.sub.10 alkyl where n is 0 to 2, and
- (f) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 groups selected from hydroxy, halogen, CO.sub.2 R.sup.4, S(O).sub.n -C.sub.1 -C.sub.10 alkyl, where n is 0 to 2, C.sub.3 -C.sub.8 cycloalkyl, C.sub.1 -C.sub.10 alkoxy, and A optionally substituted with up to 5 groups selected from halogen, C.sub.1 -C.sub.10 alkyl and C.sub.1 -C.sub.10 alkoxy;
- R.sup.3 is
- (1) R.sup.2 or
- (2) NR.sup.2 R.sup.2 ;
- R.sup.4 is
- (1) H, or
- (2) C.sub.1 -C.sub.10 alkyl;
- Q is
- (1) N(R.sup.2),
- (2) O or
- (3) S(O).sub.n, and n is 0 to 2;
- Q' is
- (1) N(R.sup.2),
- (2) O or
- (3) a bond; or
- a pharmaceutically acceptable salt thereof or a prodrug thereof.
- 2. A compound of claim 1 wherein
- R.sup.1 is
- (1) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 halogens;
- (2) halogen,
- (3) QR.sup.2,
- (4) Q'COR.sup.3,
- (5) phenyl;
- R.sup.2 is
- (1) hydrogen,
- (2) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 halogens;
- R.sup.3 is
- (1) C.sub.1 -C.sub.10 alkyl; and
- Q is
- (1) O.
- 3. A compound of claim 1 wherein
- X is
- (1) a bond;
- m is
- 0 to 5;
- A is
- (1) phenyl, or
- (2) a benzene ring fused to a C.sub.5 -C.sub.10 carbocyclic ring;
- R.sup.1 is
- (1) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 halogens;
- (2) halogen,
- (3) QR.sup.2,
- (4) Q'COR.sup.3,
- (5) phenyl;
- R.sup.2 is
- (1) hydrogen,
- (2) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 halogens;
- R.sup.3 is
- (1) C.sub.1 -C.sub.10 alkyl; and
- Q is
- (1) O.
- 4. A compound of claim 1 wherein either the benzenesulfonamide moiety or A is attached to the C2 of the thiazole ring, and the other to the C4 positions of the thiazole ring.
- 5. A compound of claim 4 wherein
- X is
- (1) a bond;
- m is
- 0 to 5;
- A is
- (1) phenyl, or
- (2) naphthyl;
- R.sup.1 is
- (1) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 halogens;
- (2) halogen,
- (3) QR.sup.2,
- (4) Q'COR.sup.3,
- (5) phenyl;
- R.sup.2 is
- (1) hydrogen,
- (2) C.sub.1 -C.sub.10 alkyl optionally substituted with up to 5 halogens;
- R.sup.3 is
- (1) C.sub.1 -C.sub.10 alkyl; and
- Q is
- (1) O.
- 6. A compound of claim 5 wherein A is selected from the group consisting of phenyl and naphthyl.
- 7. A compound of claim 1 having the formula: ##STR23##
- 8. A compound selected from the group consisting of: N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethoxy)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3,4-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-fluorophenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(2-naphthyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3,4,5trifluorophenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-hexylphenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(2,4-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3,5-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(1,1-dimethylethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(2,3-difluorophenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[3-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(difluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(2,4-dichlorophenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[2-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[2-fluoro-4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4-fluoro-2-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[2,4-bis(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[5-(4-fluorophenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[2-(4-trifluoromethylphenyl)thiazol-4-yl]benzenesulfonamide;
- N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[2-(4-trifluoromethylphenyl)thiazol-5-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-phenylphenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3,4-dihydroxyphenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-hydroxyphenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-acetoxyphenyl)thiazol-2-yl]benzenesulfonamide;
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-acetamidophenyl)thiazol-2-yl]benzenesulfonamide; and
- N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[2-(4-trifluoromethoxyphenyl)thiazol-4-yl]benzenesulfonamide.
- 9. A composition for the treatment of diabetes or obesity or for lowering triglyceride or cholesterol levels or increasing high density lipoprotein levels or for decreasing gut motility or for reducing neurogenic inflammation or for treating depression or for treating gastrointestinal disorders which comprises an inert carrier and an effective amount of a compound of claim 1.
- 10. A pharmaceutical composition which comprises a compound of formula I and a pharmaceutically acceptable carrier.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is based on, and claims priority from, provisional application No. 60/036,760 filed Jan. 28, 1997.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5451677 |
Fisher et al. |
Sep 1995 |
|
5561142 |
Fisher et al. |
Oct 1996 |
|
5705515 |
Fisher et al. |
Jan 1998 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0 091 749 |
Oct 1983 |
EPX |
0 611 003 |
Aug 1994 |
EPX |
WO 9529159 |
Nov 1995 |
WOX |